Evidence supporting product standards for carcinogens in smokeless tobacco products

Cancer Prevention Research

Volumn 8, Issue 1, 2015, Pages 20-26

  Hatsukami, Dorothy K ^a,b   Stepanov, Irina ^a   Severson, Herb ^c   Jensen, Joni A ^b   Lindgren, Bruce R ^a   Horn, Kimberly ^d   Khariwala, Samir S ^b   Martin, Julia ^c   Carmella, Steven G ^a   Murphy, Sharon E ^a   Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c OREGON RESEARCH INSTITUTE   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; NICOTINE; NITROSAMINE;

ADULT; ARTICLE; ENVIRONMENTAL EXPOSURE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MALE; MEDICAL HISTORY; PASSIVE SMOKING; PRIORITY JOURNAL; SCREENING TEST; SMOKELESS TOBACCO; TOBACCO; TOBACCO USE; UNITED STATES; URINALYSIS; ADVERSE EFFECTS; CHEMISTRY; CLINICAL TRIAL; MIDDLE AGED; MINNESOTA; MULTICENTER STUDY; OREGON; REGRESSION ANALYSIS; STANDARDS; URINE; WEST VIRGINIA;

ADULT; BIOMARKERS; CARCINOGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINNESOTA; NICOTINE; NITROSAMINES; OREGON; REGRESSION ANALYSIS; TOBACCO, SMOKELESS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WEST VIRGINIA;

EID: 84920855824     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0250     Document Type: Article

References (52)

1. Stepanov I, Jensen J, Hatsukami D, Hecht SS. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine Tob Res 2008;10:1773-82.
2. Richter P, Hodge K, Stanfill S, Zhang L, Watson C. Surveillance of moist snuff total nicotine, pH, moisture, un-ionized nicotine, and tobaccospecific nitrosamine content. Nicotine Tob Res 2008;10:1645-52.
3. Stanfill SB, Connolly GN, Zhang L, Jia LT, Henningfield JE, Richter P, et al. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control 2011;20:e2.
4. Hecht SS, Hoffmann D. Tobacco-specifi c nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988;9: 875-84.
5. Hecht SS, Hoffmann D. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv 1989;8:273-94.
6. Hoffmann D, Djordjevic MV, Fan J, Zang E, Glynn T, Connolly GN. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst 1995;87:1862-9.
7. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998;11:559-603.
8. International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific nitrosamines. IARC Monogr Eval Carcinog Risks Hum. Lyon, France: IARC; 2007.
9. International Agency for Research on Cancer.Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. Lyon, France: IARC; 2004.
10. Balbo S, James-Yi S, Johnson CS, O'Sullivan MG, Stepanov I, Wang M, et al. (S)-N′-Nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Carcinogenesis 2013;34:2178-83.
11. Stepanov I, Sebero E, Wang R, Gao YT, Hecht SS, Yuan JM. Tobacco-specific N-nitrosamine exposures and cancer risk in the Shanghai Cohort Study: remarkable coherence with rat tumor sites. Int J Cancer 2014;134:2278-83.
12. Stepanov I, Hecht SS, Ramakrishnan S, Gupta PC. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. Int J Cancer 2005;116:16-9.
13. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75.
14. World Health Organization. The scientific basis of tobacco product regulation: second report of a WHO study group. Geneva, Switzerland: World Health Organization; 2008. Report No.: 978-92-4-120951-9.
15. U.S. Department of Health and Human Services. The health consequences of smoking: nicotine and addiction. A Report of the Surgeon General.: U.S. Department of Health & Human Services; 1988. Report No.: DHHS Publication No. (CDC) 88-8406.
16. U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
17. Massachusetts Department of Health. Smokeless tobacco data base. Boston, MA; 2004.
18. Lawler TS, Stanfill SB, Zhang L, Ashley DL, Watson CH. Chemical characterization of domestic oral tobacco products: total nicotine, pH, unprotonated nicotine and tobacco-specific N-nitrosamines. Food Chem Toxicol 2013;57:380-6.
19. Akers L, Severson HH, Boles SM, Andrews JA. Development of the Severson Smokeless Tobacco Dependence scale. Eugene, OR: Oregon Research Institute; 2012. Report No.:Oregon Research Institute Tobacco Workgroup Technical Report 2011-01.
20. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737-44.
21. Selzer ML, Vinokur A, van Rooijen L. A self-administered Short Michigan Alcoholism Screening Test (SMAST). J Stud Alcohol 1975;36:117-26.
22. Hecht SS, Carmella SG, Murphy SE. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 1999;8:907-13.
23. Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-6.
24. Scherer G, Engl J, Urban M, Gilch G, Janket D, Riedel K. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul Toxicol Pharmacol 2007;47:171-83.
25. Carmella SG, Ming X, Olvera N, Brookmeyer C, Yoder A, Hecht SS. High throughput liquid and gas chromatography-tandem mass spectrometry assays for tobacco-specific nitrosamine and polycyclic aromatic hydrocarbonmetabolites associated with lung cancer in smokers. Chem Res Toxicol 2013;26:1209-17.
26. Yuan JM, Knezevich AD, Wang R, Gao YT, Hecht SS, Stepanov I. Urinary levels of the tobacco-specific carcinogen N0 -nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011;32:1366-71.
27. Stepanov I, Hecht SS. Detection and quantitation of N′-nitrosonornicotine in human toenails by liquid chromatography-electrospray ionizationtandem mass spectrometry. Cancer Epidemiol Biomarkers Prev 2008;17:945-8.
28. Stepanov I, Biener L, Knezevich A, Nyman AL, Bliss R, Jensen J, et al. Monitoring tobacco-specific N-nitrosamines and nicotine in novel Marlboro and Camel smokeless tobacco products: findings from Round 1 of the New Product Watch. Nicotine Tob Res 2012;14:274-81.
29. Alpert HR, Koh H, Connolly GN. Free nicotine content and strategic marketing of moist snuff tobacco products in the United States: 2000-2006. Tob Control 2008;17:332-8.
30. Henningfield JE, Fant RV, Tomar SL. Smokeless tobacco: an addicting drug. Adv Dent Res 1997;11:330-5.
31. Lemmonds CA, Hecht SS, Jensen JA, Murphy SE, Carmella SG, Zhang Y, et al. Smokeless tobacco topography and toxin exposure. Nicotine Tob Res 2005;7:469-74.
32. Hecht SS, Carmella SG, Ye M, Le KA, Jensen JA, Zimmerman CL, et al. Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use. Cancer Res 2002;62:129-34.
33. Hatsukami DK, Anton D, Callies A, Keenan R. Situational factors and patterns associated with smokeless tobacco use. J Behav Med 1991;14:383-96.
34. Hatsukami DK, Gust SW, Keenan RM. Physiologic and subjective changes from smokeless tobacco withdrawal. Clin Pharmacol Ther 1987;41:103-7.
35. Hatsukami DK, Keenan RM, Anton DJ. Topographical features of smokeless tobacco use. Psychopharmacology 1988;96:428-9.
36. Severson HH, Eakin EG, Lichtenstein E, Stevens VJ. The inside scoop on the stuff called snuff: an interview study of 94 adult male smokeless tobacco users. J Subst Abuse 1990;2:77-85.
37. Hatsukami DK, Lemmonds C, Zhang Y, Murphy SE, Le C, Carmella SG, et al. Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. J Natl Cancer Inst 2004;96:844-52.
38. Church TR, Anderson KE, Caporaso NE, Geisser MS, Le CT, Zhang Y, et al. A prospectivelymeasured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev 2009;18:260-6.
39. Yuan JM, Koh WP, Murphy SE, Fan Y, Wang R, Carmella SG, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res 2009;69:2990-5.
40. Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, et al. Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Res 2011;71:6749-57.
41. Hecht SS, Rivenson A, Braley J, DiBellow J, Adams JD, Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res 1986;46:4162-6.
42. Magee PN. The experimental basis for the role of nitroso compounds in human cancer. Cancer Surv 1989;8:207-39.
43. Preston-Martin S, Correa P. Epidemiological evidence for the role of nitroso compounds in human cancer. Cancer Surv 1989;8:459-73.
44. Madani AH, Dikshit M, Bhaduri D. Risk for oral cancer associated to smoking, smokeless and oral dip products. Indian J Public Health 2012;56:57-60.
45. Chaturvedi P, Vaishampayan SS, Nair S, Nair D, Agarwal JP, Kane SV, et al. Oral squamous cell carcinoma arising in background of oral submucous fibrosis: a clinicopathologically distinct disease. Head Neck 2013;35:1404-9.
46. Kresty LA, Carmella SG, Borukhova A, Akerkar SA, Gopalakrishnan R, Harris RE, et al. Metabolites of a tobacco-specific nitrosamine, 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. Cancer Epidemiol Biomarkers Prev 1996;5:521-5.
47. Rutqvist LE, Curvall M, Hassler T, Ringberger T, Wahlberg I. Swedish snus and the GothiaTek(R) standard. Harm Reduct J 2011;8:11.
48. Swedish Match website; 2014 [2014 Sept 29]. Available from: http://www.swedishmatch.com/en/Snus-and-health/GOTHIATEK/GOTHIATEK-standard/
49. Hecht SS, Carmella SG, Edmonds A, Murphy SE, Stepanov I, Luo X, et al. Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco. Tob Control 2008;17:128-31.
50. Ebbert JO, Edmonds A, Luo X, Jensen J, Hatsukami DK. Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention. Nicotine Tob Res 2010;12:823-7.
51. Hatsukami DK, Ebbert JO, Edmonds A, Li C, Lin H, Le C, et al. Smokeless tobacco reduction: preliminary study of tobacco-free snuff versus no snuff. Nicotine Tob Res 2008;10:77-85.
52. Ninomiya F, Yokohira M, Kishi S, Nakano Y, Yamakawa K, Inoue T, et al. Gender-dependent effects of gonadectomy on lung carcinogenesis by 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female and male A/J mice. Oncol Rep 2013;30:2632-8.